Fufeng Wang
YOU?
Author Swipe
View article: Genetic alterations and aberrant hormonal pathways in thymic epithelial tumors
Genetic alterations and aberrant hormonal pathways in thymic epithelial tumors Open
View article: DECIPHER-PRAD: an advanced fragmentomics-based cell-free DNA assay for prostate cancer early detection
DECIPHER-PRAD: an advanced fragmentomics-based cell-free DNA assay for prostate cancer early detection Open
Early detection of prostate cancer is limited by the poor specificity of prostate-specific antigen (PSA)-based screening. Cell-free DNA (cfDNA) fragmentomics offers a promising non-invasive approach to improve screening accuracy and risk s…
View article: Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA
Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA Open
Identification of clinical and genetic biomarkers for recurrence risk prediction in resected melanoma may aid in clinical decision-making for early disease monitoring and optimal design of therapeutic strategies.
View article: Predictive and prognostic value of genetic aberrations of EGFR-TKI treatment: a real-world analysis of EGFR-mutant non-small cell lung cancer
Predictive and prognostic value of genetic aberrations of EGFR-TKI treatment: a real-world analysis of EGFR-mutant non-small cell lung cancer Open
This study identified key biomarkers associated with the efficacy of EGFR-TKIs and survival in patients with EGFRm NSCLC, thereby providing new insights for personalized therapeutic strategies based on genetic risk stratification.
View article: Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis
Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis Open
Introduction Neoadjuvant chemotherapy (NAC) is a standard treatment for breast cancer (BC) to shrink tumors and facilitate surgery. However, the molecular underpinnings of response to NAC and prognosis have not been well characterized. Met…
View article: Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer
Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer Open
PURPOSE Pancreatic ductal adenocarcinoma (PDAC), known for its high fatality rate, is often diagnosed in its advanced stages where surgical options are not viable. This highlights the critical need for innovative and effective early detect…
View article: Figure S1 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
Figure S1 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer Open
Figure S1
View article: Figure S4 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
Figure S4 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer Open
Figure S4
View article: Data from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
Data from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer Open
Colorectal cancer is frequently diagnosed in advanced stages, highlighting the need for developing approaches for early detection. Liquid biopsy using cell-free DNA (cfDNA) fragmentomics is a promising approach, but the clinical applicatio…
View article: Figure S5 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
Figure S5 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer Open
Figure S5
View article: Figure S2 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
Figure S2 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer Open
Figure S2
View article: Figure S3 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
Figure S3 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer Open
Figure S3
View article: Supplementary Data from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
Supplementary Data from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer Open
Supplementary Data
View article: Molecular evolution of intestinal-type early gastric cancer according to Correa cascade
Molecular evolution of intestinal-type early gastric cancer according to Correa cascade Open
Early screening is crucial for the prevention of intestinal-type gastric cancer. The current study aimed to ascertain the molecular evolution of intestinal-type gastric cancer based on the Correa cascade for precise gastric cancer screenin…
View article: Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy
Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy Open
For ES-SCLC patients receiving first-line chemoimmunotherapy, alterations in DLL3, KMT2B, HGF, EPHA3, and ADGRB3 and a greater proportion of M1-like macrophages infiltration in all locations were predictors of favorable survival, while MCL…
View article: Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma
Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma Open
View article: Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma Open
Background Previous studies have suggested the potential synergistic antitumor activity when combining immune checkpoint inhibitors with anti-angiogenic agents in various solid tumors. We aimed to assess the efficacy and safety of camreliz…
View article: Molecular characteristics of early-onset compared with late-onset colorectal cancer: a case controlled study
Molecular characteristics of early-onset compared with late-onset colorectal cancer: a case controlled study Open
Background: Early-onset colorectal cancer (EOCRC) is associated with a poorer prognosis relative to late-onset colorectal cancer (LOCRC), and its incidence has witnessed a gradual escalation in recent years. This necessitates a comprehensi…
View article: <i>KMT2A</i> Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer
<i>KMT2A</i> Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer Open
The conventional treatment strategies for patients with metastatic colorectal cancer (mCRC) are predominantly guided by the status of RAS and BRAF mutations. Although patients may exhibit analogous pathological characteristics and undergo …
View article: Case Report: Cancer spectrum and genetic characteristics of a de novo germline POLD1 p.L606M variant-induced polyposis syndrome
Case Report: Cancer spectrum and genetic characteristics of a de novo germline POLD1 p.L606M variant-induced polyposis syndrome Open
Germline variations in the DNA polymerase genes, POLE and POLD1 , can lead to a hereditary cancer syndrome that is characterized by frequent gastrointestinal polyposis and multiple primary malignant tumors. However, because of its rare occ…
View article: Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution
Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution Open
Background Lung cancer is the deadliest and most diagnosed type of cancer worldwide. The 5-year survival rate of lung adenocarcinoma (LUAD) dropped significantly when tumor stages advanced. Patients who received surgically resecting at the…
View article: Table S3 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S3 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Influence of histology on survival analyses
View article: Table S1 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S1 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Detailed individual characteristics of each patient
View article: Table S5 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S5 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Copy number alterations in genes in immune-related pathways in each patient
View article: Data from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Data from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Purpose:Immune checkpoint inhibitors (ICI) have revolutionized cancer management. However, molecular determinants of response to ICIs remain incompletely understood.Experimental Design:We performed genomic profiling of 78 patients with non…
View article: Table S5 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S5 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Copy number alterations in genes in immune-related pathways in each patient
View article: Table S2 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S2 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Individual gene mutations correlate with immunotherapy response in both Rizvi et al and our data
View article: Table S4 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S4 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Copy number alterations correlate with immunotherapy response in both Miao et al and our data
View article: Table S3 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S3 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Influence of histology on survival analyses
View article: Table S1 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Table S1 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer Open
Detailed individual characteristics of each patient